Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 14;1(3):348-66.
doi: 10.3390/vaccines1030348.

An HIV Vaccine for South-East Asia-Opportunities and Challenges

Punnee Pitisuttithum  1 , Supachai Rerks-Ngarm  2 , Robert J O'Connell  3 , Jerome H Kim  4 , Jean-Louis Excler  5
Affiliations

An HIV Vaccine for South-East Asia-Opportunities and Challenges

Punnee Pitisuttithum et al. Vaccines (Basel). .

Abstract

Recent advances in HIV vaccine development along with a better understanding of the immune correlates of risk have emerged from the RV144 efficacy trial conducted in Thailand. Epidemiological data suggest that CRF01_AE is still predominant in South-East Asia and is spreading in China with a growing number of circulating recombinant forms due to increasing human contact, particularly in large urban centers, tourist locations and in sites of common infrastructure. A vaccine countering CRF01_AE is a priority for the region. An Asia HIV vaccine against expanding B/E or BCE recombinant forms should be actively pursued. A major challenge that remains is the conduct of efficacy trials in heterosexual populations in this region. Men who have sex with men represent the main target population for future efficacy trials in Asia. Coupling HIV vaccines with other prevention modalities in efficacy trials might also be envisaged. These new avenues will only be made possible through the conduct of large-scale efficacy trials, interdisciplinary teams, international collaborations, and strong political and community commitments.

Keywords: China; HIV vaccines; HIV-1 subtypes; Men who have sex with men; Myanmar; RV144; South-East Asia; Thailand; correlates of risk; efficacy trials.

PubMed Disclaimer

References

    1. United Nations Economic and Social Commission for Asia and the Pacific. Statistical Yearbook for Asia and the Pacific. Bangkok, Thailand: 2011.
    1. Lo Y.R., Nguyen T.T.T., Srikantiah P., Excler J.L., Ghidinelli M., Narain J.P. AIDS in Asia and the Pacific. In: Hall J.C., Hall B.J., Cockerell C.J., editors. HIV/AIDS in the Post-HAART Era: Manifestations, Treatment, and Epidemiology. People’s Medical Publishing House; Shelton, CT, USA: 2011. pp. 839–864.
    1. Srikantiah P., Ghidinelli M., Bachani D., Chasombat S., Daoni E., Mustikawati D.E., Nhan D.T., Pathak L.R., San K.O., Vun M.C., et al. Scale-up of national antiretroviral therapy programs: Progress and challenges in the Asia Pacific region. AIDS. 2010;24:S62–S71. doi: 10.1097/01.aids.0000390091.45435.ea. - DOI - PubMed
    1. Joint United Nations Programme on HIV/AIDS. HIV in Asia and the Pacific: Getting to Zero. Bangkok, Thailand: 2011.
    1. DeGruttola V., Smith D.M., Little S.J., Miller V. Developing and evaluating comprehensive HIV infection control strategies: Issues and challenges. Clin. Infect. Dis. 2010;50:S102–S107. doi: 10.1086/651480. - DOI - PMC - PubMed